Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Coursera Inc (COUR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Coursera Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Coursera Inc trades at $5.65 (market cap $1.52B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 6.2× Coursera Inc's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Coursera Inc nearer its low. Which is the better fit depends on your goals.
| BIO | COUR | |
|---|---|---|
Market Cap | $9.39B | $1.52B |
Sector | Health | Consumer Staples |
52-Week High | $356.25 | $12.20 |
52-Week Low | $241.71 | $5.09 |
Enterprise Value | $9.14B | $778.04M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
Coursera (COUR) trades at $5.81, up 4.5% with bullish technical signals and strong analyst support. The company shows improving revenue growth ($757.5M in 2025, projected to $885M in 2026) but remains unprofitable with negative margins. Recent Q2 2026 earnings beat expectations with $0.17 EPS versus $0.10 estimate, while the company made a strategic $100M investment in AI education startup LearnVector.
The stock offers 32% upside to consensus price target of $7.70, supported by 53% buy ratings, but faces execution risks from persistent losses and competitive pressures in online education. Revenue growth trajectory and cost management will be critical for valuation improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →
